Search

Your search keyword '"Ristamäki, Raija"' showing total 175 results
Start Over Author "Ristamäki, Raija"
175 results on '"Ristamäki, Raija"'

1. Short-course preoperative radiotherapy increases pelvic fracture risk in rectal cancer

Author

Väliaho Vesa, Mäkitalo Jaana, Kohonen Ia, Carpelan Anu, Minn Heikki, Ristamäki Raija, Ålgars Annika, and Heervä Eetu

Subjects
Rectal cancer, Neoadjuvant, Radiotherapy, Chemoradiotherapy, Fracture, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Pelvic insufficiency fractures (PIFs) are adverse events associated with chemoradiotherapy (CRT) administered preoperatively in rectal cancer, with incidences of 0–33.6% reported in the literature. Data on PIFs after 5 × 5 Gy fractionated short-course radiotherapy (SCRT) using highly conformal radiotherapy techniques such as volumetric modulated arc therapy (VMAT) is limited. Methods: The Turku University Hospital colorectal cancer database was searched for patients operated on for stage I–III rectal cancer during the years 2014–2018. The hospital’s routine follow-up includes a 2-year computed tomography (CT) scan, which was systemically re-evaluated to detect PIFs. Only radiotherapy delivered using VMAT and image-guided approaches was included. Baseline demographics, tumor data, and dose-volume data were collected to identify risk factors for PIFs. Results: Median time to CT scan was 24 months. Among the 164 patients analyzed, the 2-year PIF incidence was 22.2% for SCRT (n = 12/54, OR 9.1 (CI95% 1.9–42.9), p = 0.004), 9.1% for CRT (n = 4/44, OR 3.2 (CI95% 0.6–18.3), p = 0.13) and 3.0% (n = 2/66, reference) for those operated on without radiotherapy. The PIF incidence was not explained by differences in dose-volume data in either the SCRT or CRT groups. Fracture risk was higher in women, up to 50% after SCRT. Conclusions: Every fifth patient treated with SCRT and rectal surgery presented with a PIF. Critical bony structures to be avoided during radiotherapy contouring could not be identified. Clinicians, especially those involved with the follow-up of rectal cancer, should be aware of this potentially debilitating and surprisingly common adverse event.

Published
2023
Full Text
View/download PDF

2. Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

Author

Uutela, Aki, Osterlund, Emerik, Halonen, Päivi, Kallio, Raija, Ålgars, Annika, Salminen, Tapio, Lamminmäki, Annamarja, Soveri, Leena-Maija, Ristamäki, Raija, Lehtomäki, Kaisa, Stedt, Hanna, Heervä, Eetu, Muhonen, Timo, Kononen, Juha, Nordin, Arno, Ovissi, Ali, Kytölä, Soili, Keinänen, Mauri, Sundström, Jari, Nieminen, Lasse, Mäkinen, Markus J., Kuopio, Teijo, Ristimäki, Ari, Isoniemi, Helena, and Osterlund, Pia

Published
2022
Full Text
View/download PDF

3. Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)

Author

Aho, Sonja, primary, Osterlund, Emerik, additional, Ristimäki, Ari, additional, Nieminen, Lasse, additional, Sundström, Jari, additional, Mäkinen, Markus J., additional, Kuopio, Teijo, additional, Kytölä, Soili, additional, Ålgars, Annika, additional, Ristamäki, Raija, additional, Heervä, Eetu, additional, Kallio, Raija, additional, Halonen, Päivi, additional, Soveri, Leena-Maija, additional, Nordin, Arno, additional, Uutela, Aki, additional, Salminen, Tapio, additional, Stedt, Hanna, additional, Lamminmäki, Annamarja, additional, Muhonen, Timo, additional, Kononen, Juha, additional, Glimelius, Bengt, additional, Isoniemi, Helena, additional, Lehto, Juho T., additional, Lehtomäki, Kaisa, additional, and Osterlund, Pia, additional

Published
2024
Full Text
View/download PDF

5. Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)

Author

Aho, Sonja, Österlund, Emerik, Ristimäki, Ari, Nieminen, Lasse, Sundström, Jari, Mäkinen, Markus J., Kuopio, Teijo, Kytölä, Soili, Ålgars, Annika, Ristamäki, Raija, Heervä, Eetu, Kallio, Raija, Halonen, Päivi, Soveri, Leena-Maija, Nordin, Arno, Uutela, Aki, Salminen, Tapio, Stedt, Hanna, Lamminmäki, Annamarja, Muhonen, Timo, Kononen, Juha, Glimelius, Bengt, Isoniemi, Helena, Lehto, Juho T., Lehtomäki, Kaisa, Österlund, Pia, Aho, Sonja, Österlund, Emerik, Ristimäki, Ari, Nieminen, Lasse, Sundström, Jari, Mäkinen, Markus J., Kuopio, Teijo, Kytölä, Soili, Ålgars, Annika, Ristamäki, Raija, Heervä, Eetu, Kallio, Raija, Halonen, Päivi, Soveri, Leena-Maija, Nordin, Arno, Uutela, Aki, Salminen, Tapio, Stedt, Hanna, Lamminmäki, Annamarja, Muhonen, Timo, Kononen, Juha, Glimelius, Bengt, Isoniemi, Helena, Lehto, Juho T., Lehtomäki, Kaisa, and Österlund, Pia

Abstract

Simple Summary The location of the primary tumor in the right colon, left colon, or rectum affects the efficacy of biological drugs used in the treatment of metastatic colorectal cancer, but how? We examined how the primary tumor location affects disease characteristics, treatability, quality of life, and outcome in a real-life study population of 1080 Finnish patients in the RAXO study. The primary tumor location correlates with the location of metastases, the frequency of gene mutations, how often metastases can be operated upon, long-term survival after curative surgery or palliative chemotherapy, and the quality of life during the disease trajectory. The primary tumor location is a helpful surrogate for clinicians working with metastatic colorectal cancer patients in estimating the clinical course of the disease. This study cannot identify the reasons for the associations, i.e., whether it is the primary location per se, the different mutations, or other reasons.Abstract The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population (n = 1080). Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kaplan-Meier, and Cox regression were used to compare the groups. The PTL was in the right colon in 310 patients (29%), the left colon in 396 patients (37%), and the rectum in 375 patients (35%). The PTL was associated with distinct differences in metastatic sites during the disease trajectory. The resectability, conversion, and resection rates were lowest in the right colon, followed by the rectum, and were highest in the left colon. Overall survival was shortest for right colon compared with left colon or rectal PTL (median 21 vs. 35 vs.

Published
2024
Full Text
View/download PDF

6. Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts

Author

Österlund, Emerik, Ristimäki, Ari, Mäkinen, Markus J., Kytölä, Soili, Kononen, Juha, Pfeiffer, Per, Soveri, Leena‐Maija, Keinänen, Mauri, Sorbye, Halfdan, Nunes, Luís, Salminen, Tapio, Nieminen, Lasse, Uutela, Aki, Halonen, Päivi, Ålgars, Annika, Sundström, Jari, Kallio, Raija, Ristamäki, Raija, Lamminmäki, Annamarja, Stedt, Hanna, Heervä, Eetu, Kuopio, Teijo, Sjöblom, Tobias, Isoniemi, Helena, Glimelius, Bengt, Osterlund, Pia, Österlund, Emerik, Ristimäki, Ari, Mäkinen, Markus J., Kytölä, Soili, Kononen, Juha, Pfeiffer, Per, Soveri, Leena‐Maija, Keinänen, Mauri, Sorbye, Halfdan, Nunes, Luís, Salminen, Tapio, Nieminen, Lasse, Uutela, Aki, Halonen, Päivi, Ålgars, Annika, Sundström, Jari, Kallio, Raija, Ristamäki, Raija, Lamminmäki, Annamarja, Stedt, Hanna, Heervä, Eetu, Kuopio, Teijo, Sjöblom, Tobias, Isoniemi, Helena, Glimelius, Bengt, and Osterlund, Pia

Abstract

BRAF-V600E mutation (mt) is a strong negative prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). Non-V600Emt, designated atypical BRAFmt (aBRAFmt) are rare, and little is known about their frequency, co-mutations and prognostic and predictive role. These were compared between mutational groups of mCRC patients collected from three Nordic population-based or real-world cohorts. Pathology of aBRAFmt was studied. The study included 1449 mCRC patients with 51 (3%) aBRAFmt, 182 (13%) BRAF-V600Emt, 456 (31%) RAS&BRAF wild-type (wt) and 760 (52%) RASmt tumours. aBRAFmt were seen in 2% of real-world and 4% of population-based cohorts. Twenty-six different aBRAFmt were detected, 11 (22%) class 2 (serrated adenocarcinoma in 2/9 tested), 32 (64%) class 3 (serrated in 15/25) and 4 (8%) unclassified. aBRAFmt patients were predominantly male, had more rectal primaries, less peritoneal metastases, deficient mismatch repair in one (2%), and better survival after metastasectomy (89% 5-year overall survival [OS]-rate) compared with BRAF-V600Emt. aBRAFmt and BRAF-V600Emt had poorer performance status and received fewer treatment lines than RAS&BRAFwt and RASmt. OS among aBRAFmt (median 14.4 months) was longer than for BRAF-V600Emt (11.2 months), but shorter than for RAS&BRAFwt (30.5 months) and RASmt (23.4 months). Addition of bevacizumab trended for better OS for the aBRAFmt. Nine patients with aBRAFmt received cetuximab/panitumumab without response. aBRAFmt represents a distinct subgroup differing from other RAS/BRAF groups, with serrated adenocarcinoma in only half. OS for patients with aBRAFmt tumours was slightly better than for BRAF-V600Emt, but worse than for RASmt and RAS&BRAFwt. aBRAFmt should not be a contraindication for metastasectomy.

Published
2024
Full Text
View/download PDF

7. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

Author

Cardiologie, Team Medisch, Circulatory Health, Cancer, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Kinos, Sampsa, Hagman, Helga, Halonen, Päivi, Soveri, Leena Maija, O'Reilly, Mary, Pfeiffer, Per, Frödin, Jan Erik, Sorbye, Halfdan, Heervä, Eetu, Liposits, Gabor, Kallio, Raija, Ålgars, Annika, Ristamäki, Raija, Salminen, Tapio, Bärlund, Maarit, Shah, Carl Henrik, McDermott, Ray, Röckert, Rebecka, Flygare, Petra, Kwakman, Johannes, Teske, Arco, Punt, Cornelis, Glimelius, Bengt, Österlund, Pia, Cardiologie, Team Medisch, Circulatory Health, Cancer, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Kinos, Sampsa, Hagman, Helga, Halonen, Päivi, Soveri, Leena Maija, O'Reilly, Mary, Pfeiffer, Per, Frödin, Jan Erik, Sorbye, Halfdan, Heervä, Eetu, Liposits, Gabor, Kallio, Raija, Ålgars, Annika, Ristamäki, Raija, Salminen, Tapio, Bärlund, Maarit, Shah, Carl Henrik, McDermott, Ray, Röckert, Rebecka, Flygare, Petra, Kwakman, Johannes, Teske, Arco, Punt, Cornelis, Glimelius, Bengt, and Österlund, Pia

Published
2024

8. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

Author

Kinos, Sampsa, Hagman, Helga, Halonen, Päivi, Soveri, Leena-Maija, O'Reilly, Mary, Pfeiffer, Per, Frödin, Jan-Erik, Sorbye, Halfdan, Heervä, Eetu, Liposits, Gabor, Kallio, Raija, Ålgars, Annika, Ristamäki, Raija, Salminen, Tapio, Bärlund, Maarit, Shah, Carl-Henrik, Mcdermott, Ray, Röckert, Rebecka, Flygare, Petra, Kwakman, Johannes, Teske, Arco, Punt, Cornelis, Glimelius, Bengt, Österlund, Pia, Kinos, Sampsa, Hagman, Helga, Halonen, Päivi, Soveri, Leena-Maija, O'Reilly, Mary, Pfeiffer, Per, Frödin, Jan-Erik, Sorbye, Halfdan, Heervä, Eetu, Liposits, Gabor, Kallio, Raija, Ålgars, Annika, Ristamäki, Raija, Salminen, Tapio, Bärlund, Maarit, Shah, Carl-Henrik, Mcdermott, Ray, Röckert, Rebecka, Flygare, Petra, Kwakman, Johannes, Teske, Arco, Punt, Cornelis, Glimelius, Bengt, and Österlund, Pia

Abstract

Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of the European Medicines Agency approval of S-1 in metastatic colorectal cancer (mCRC), this analysis provides more detailed safety and efficacy information, and data regarding metastasectomy and/or local ablative therapy (LAT), on the mCRC patients from the original study. Materials and methods: This retrospective cohort study was conducted at 12 European centers. The primary endpoint was recurrence of cardiotoxicity after switch. For this analysis, safety data are reported for 78 mCRC patients from the CardioSwitch cohort (N = 200). Detailed efficacy and outcomes data were available for 66 mCRC patients. Results: Data for the safety of S-1 in mCRC patients were similar to the original CardioSwitch cohort and that expected for FP-based treatment, with no new concerns. Recurrent cardiotoxicity (all grade 1) with S-1-based treatment occurred in 4/78 (5%) mCRC patients; all were able to complete FP treatment. Median progression-free survival from initiation of S-1-based treatment was 9.0 months and median overall survival 26.7 months. Metastasectomy and/or LAT was performed in 33/66 (50%) patients, and S-1 was successfully used in recommended neoadjuvant/conversion or adjuvant-like combination regimens and schedules as for standard FPs. Interpretation: S-1 is a safe and effective FP alternative when mCRC patients are forced to discontinue 5-FU or capecitabine due to cardiotoxicity and can be safely used in the standard recommended regimens, settings, and schedules.

Published
2024
Full Text
View/download PDF

11. Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts

Author

Osterlund, Emerik, primary, Ristimäki, Ari, additional, Mäkinen, Markus J., additional, Kytölä, Soili, additional, Kononen, Juha, additional, Pfeiffer, Per, additional, Soveri, Leena‐Maija, additional, Keinänen, Mauri, additional, Sorbye, Halfdan, additional, Nunes, Luís, additional, Salminen, Tapio, additional, Nieminen, Lasse, additional, Uutela, Aki, additional, Halonen, Päivi, additional, Ålgars, Annika, additional, Sundström, Jari, additional, Kallio, Raija, additional, Ristamäki, Raija, additional, Lamminmäki, Annamarja, additional, Stedt, Hanna, additional, Heervä, Eetu, additional, Kuopio, Teijo, additional, Sjöblom, Tobias, additional, Isoniemi, Helena, additional, Glimelius, Bengt, additional, and Osterlund, Pia, additional

Published
2023
Full Text
View/download PDF

14. Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)

Author

Lehtomäki, Kaisa, primary, Soveri, Leena-Maija, additional, Osterlund, Emerik, additional, Lamminmäki, Annamarja, additional, Uutela, Aki, additional, Heervä, Eetu, additional, Halonen, Päivi, additional, Stedt, Hanna, additional, Aho, Sonja, additional, Muhonen, Timo, additional, Ålgars, Annika, additional, Salminen, Tapio, additional, Kallio, Raija, additional, Nordin, Arno, additional, Aroviita, Laura, additional, Nyandoto, Paul, additional, Kononen, Juha, additional, Glimelius, Bengt, additional, Ristamäki, Raija, additional, Isoniemi, Helena, additional, and Osterlund, Pia, additional

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Materials and Methods, Figure Legends, Tables 1 - 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, primary, Thiébaut, Raphaële, primary, Liébaert, François, primary, Fontaine, Karine, primary, Rousseau, Francis, primary, Génin, Bérengère, primary, Corre, Delphine Le, primary, Didelot, Audrey, primary, Vincent, Marc, primary, Bachet, Jean-Baptiste, primary, Chibaudel, Benoist, primary, Bouché, Olivier, primary, Landi, Bruno, primary, Bibeau, Frédéric, primary, Leroy, Karen, primary, Penault-Llorca, Frédérique, primary, Van Laethem, Jean-Luc, primary, Demetter, Pieter, primary, Tejpar, Sabine, primary, Rossi, Simona, primary, Mosakhani, Neda, primary, Österlund, Pia, primary, Ristamäki, Raija, primary, Sarhadi, Virinder, primary, Knuutila, Sakari, primary, Boige, Valérie, primary, André, Thierry, primary, and Laurent-Puig, Pierre, primary

Published
2023
Full Text
View/download PDF

21. Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)

Author

Lehtomäki, Kaisa, Soveri, Leena-Maija, Österlund, Emerik, Lamminmäki, Annamarja, Uutela, Aki, Heervä, Eetu, Halonen, Päivi, Stedt, Hanna, Aho, Sonja, Muhonen, Timo, Ålgars, Annika, Salminen, Tapio, Kallio, Raija, Nordin, Arno, Aroviita, Laura, Nyandoto, Paul, Kononen, Juha, Glimelius, Bengt, Ristamäki, Raija, Isoniemi, Helena, Osterlund, Pia, Lehtomäki, Kaisa, Soveri, Leena-Maija, Österlund, Emerik, Lamminmäki, Annamarja, Uutela, Aki, Heervä, Eetu, Halonen, Päivi, Stedt, Hanna, Aho, Sonja, Muhonen, Timo, Ålgars, Annika, Salminen, Tapio, Kallio, Raija, Nordin, Arno, Aroviita, Laura, Nyandoto, Paul, Kononen, Juha, Glimelius, Bengt, Ristamäki, Raija, Isoniemi, Helena, and Osterlund, Pia

Abstract

Older adults are underrepresented in metastatic colorectal cancer (mCRC) studies and thus may not receive optimal treatment, especially not metastasectomies. The prospective Finnish real-life RAXO-study included 1086 any organ mCRC patients. We assessed repeated centralized resectability, overall survival (OS), and quality of life (QoL) using 15D and EORTC QLQ-C30/CR29. Older adults (>75 years; n = 181, 17%) had worse ECOG performance status than adults (<75 years, n = 905, 83%), and their metastases were less likely upfront resectable. The local hospitals underestimated resectability in 48% of older adults and in 34% of adults compared with the centralized multidisciplinary team (MDT) evaluation (p < 0.001). The older adults compared with adults were less likely to undergo curative-intent R0/1-resection (19% vs. 32%), but when resection was achieved, OS was not significantly different (HR 1.54 [CI 95% 0.9–2.6]; 5-year OS-rate 58% vs. 67%). ‘Systemic therapy only’ patients had no age-related survival differences. QoL was similar in older adults and adults during curative treatment phase (15D 0.882–0.959/0.872–0.907 [scale 0–1]; GHS 62–94/68–79 [scale 0–100], respectively). Complete curative-intent resection of mCRC leads to excellent survival and QoL even in older adults. Older adults with mCRC should be actively evaluated by a specialized MDT and offered surgical or local ablative treatment whenever possible.

Published
2023
Full Text
View/download PDF

22. Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study

Author

RAXO Study Group, Uutela, Aki, Nordin, Arno, Osterlund, Emerik, Halonen, Päivi, Kallio, Raija, Soveri, Leena-Maija, Salminen, Tapio, Ålgars, Annika, Ristimäki, Ari, Ovissi, Ali, Lamminmäki, Annamarja, Muhonen, Timo, Kononen, Juha, Ristamäki, Raija, Heervä, Eetu, Stedt, Hanna, Lehtomäki, Kaisa, Kytölä, Soili, Sundström, Jari, Mäkinen, Markus J, Nieminen, Lasse, Kuopio, Teijo, Keinänen, Mauri, Osterlund, Pia, Isoniemi, Helena, Tampere University, Department of Oncology, Clinical Medicine, Department of Pathology, and Department of Clinical Chemistry

Subjects
3122 Cancers, Surgery, 3121 Internal medicine
Abstract

publishedVersion

Published
2022

23. Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.

Author

Uutela, Aki, Nordin, Arno, Osterlund, Emerik, Halonen, Päivi, Kallio, Raija, Soveri, Leena-Maija, Salminen, Tapio, Ålgars, Annika, Ristimäki, Ari, Ovissi, Ali, Lamminmäki, Annamarja, Muhonen, Timo, Kononen, Juha, Ristamäki, Raija, Heervä, Eetu, Stedt, Hanna, Lehtomäki, Kaisa, Kytölä, Soili, Sundström, Jari, and Mäkinen, Markus J.

Subjects
COLORECTAL liver metastasis, BRAF genes, LONGITUDINAL method
Published
2023
Full Text
View/download PDF

27. Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study

Author

Lehtomäki, Kaisa, primary, Stedt, Hanna P., additional, Osterlund, Emerik, additional, Muhonen, Timo, additional, Soveri, Leena-Maija, additional, Halonen, Päivi, additional, Salminen, Tapio K., additional, Kononen, Juha, additional, Kallio, Raija, additional, Ålgars, Annika, additional, Heervä, Eetu, additional, Lamminmäki, Annamarja, additional, Uutela, Aki, additional, Nordin, Arno, additional, Lehto, Juho, additional, Saarto, Tiina, additional, Sintonen, Harri, additional, Kellokumpu-Lehtinen, Pirkko-Liisa, additional, Ristamäki, Raija, additional, Glimelius, Bengt, additional, Isoniemi, Helena, additional, and Osterlund, Pia, additional

Published
2022
Full Text
View/download PDF

28. KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

Author

Osterlund, Emerik, primary, Ristimäki, Ari, additional, Kytölä, Soili, additional, Kuopio, Teijo, additional, Heervä, Eetu, additional, Muhonen, Timo, additional, Halonen, Päivi, additional, Kallio, Raija, additional, Soveri, Leena-Maija, additional, Sundström, Jari, additional, Keinänen, Mauri, additional, Ålgars, Annika, additional, Ristamäki, Raija, additional, Sorbye, Halfdan, additional, Pfeiffer, Per, additional, Nunes, Luís, additional, Salminen, Tapio, additional, Lamminmäki, Annamarja, additional, Mäkinen, Markus J., additional, Sjöblom, Tobias, additional, Isoniemi, Helena, additional, Glimelius, Bengt, additional, and Osterlund, Pia, additional

Published
2022
Full Text
View/download PDF

29. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO) : A nationwide prospective intervention study

Author

Osterlund, Pia, Salminen, Tapio, Soveri, Leena-Maija, Kallio, Raija, Kellokumpu, Ilmo, Lamminmäki, Annamarja, Halonen, Päivi, Ristamäki, Raija, Lantto, Eila, Uutela, Aki, Österlund, Emerik, Ovissi, Ali, Nordin, Arno, Heervä, Eetu, Lehtomäki, Kaisa, Räsänen, Jari, Murashev, Maija, Aroviita, Laura, Jekunen, Antti, Lindvall-Andersson, Renee, Nyandoto, Paul, Kononen, Juha, Lepistö, Anna, Poussa, Tuija, Muhonen, Timo, Ålgars, Annika, Isoniemi, Helena, Osterlund, Pia, Salminen, Tapio, Soveri, Leena-Maija, Kallio, Raija, Kellokumpu, Ilmo, Lamminmäki, Annamarja, Halonen, Päivi, Ristamäki, Raija, Lantto, Eila, Uutela, Aki, Österlund, Emerik, Ovissi, Ali, Nordin, Arno, Heervä, Eetu, Lehtomäki, Kaisa, Räsänen, Jari, Murashev, Maija, Aroviita, Laura, Jekunen, Antti, Lindvall-Andersson, Renee, Nyandoto, Paul, Kononen, Juha, Lepistö, Anna, Poussa, Tuija, Muhonen, Timo, Ålgars, Annika, and Isoniemi, Helena

Abstract

Background: Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. Methods: A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the assessment of resectability upfront and twice during first-line therapy by the multidisciplinary team (MDT) at Helsinki tertiary referral centre. The primary outcome was resection rates and survival. Findings: In 2012-2018, 1086 patients were included. Median follow-up was 58 months. Multiple metastatic sites were present in 500 (46%) patients at baseline and in 820 (76%) during disease trajectory. In MDT assessments, 447 (41%) were classified as resectable, 310 (29%) upfront and 137 (18%) after conversion therapy. Sixhundred and ninety curative intent resections or local ablative therapies (LAT) were performed in 399 patients (89% of 447 resectable). Multiple metastasectomies for multisite or later developing metastases were performed in 148 (37%) patients. Overall, 414 liver, 112 lung, 57 peritoneal, and 107 other metastasectomies were performed. Median OS was 80.4 months in R0/1-resected (HR 0.15; CI95% 0.12-0.19), 39.1 months in R2-resected/LAT (0.39; 0.29-0.53) patients, and 20.8 months in patients treated with "systemic therapy alone" (reference), with 5-year OS rates of 66%, 40%, and 6%, respectively. Interpretation: Repeated centralized MDT assessment in real-world metastatic CRC patients generates high resectability (41%) and resection rates (37%) with impressive survival, even when multisite metastases are present or develop later.

Published
2021
Full Text
View/download PDF

30. An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer

Author

Heervä, Eetu, Väliaho, Vesa, Salminen, Tapio, Nieminen, Lasse, Carpelan, Anu, Kurki, Samu, Sundström, Jari, Huhtinen, Heikki, Rantala, Arto, Carpen, Olli, Minn, Heikki, Österlund, Pia, Ålgars, Annika, Ristamäki, Raija, HUSLAB, Precision Cancer Pathology, Department of Pathology, Olli Mikael Carpen / Principal Investigator, Research Program in Systems Oncology, Research Programs Unit, University of Helsinki, and Helsinki University Hospital Area

Subjects
ADJUVANT CHEMOTHERAPY, education, 3122 Cancers, RECURRENCE, THERAPY, COLORECTAL-CANCER
Abstract

Non

Published
2020

31. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study

Author

Osterlund, Pia, primary, Salminen, Tapio, additional, Soveri, Leena-Maija, additional, Kallio, Raija, additional, Kellokumpu, Ilmo, additional, Lamminmäki, Annamarja, additional, Halonen, Päivi, additional, Ristamäki, Raija, additional, Lantto, Eila, additional, Uutela, Aki, additional, Osterlund, Emerik, additional, Ovissi, Ali, additional, Nordin, Arno, additional, Heervä, Eetu, additional, Lehtomäki, Kaisa, additional, Räsänen, Jari, additional, Murashev, Maija, additional, Aroviita, Laura, additional, Jekunen, Antti, additional, Lindvall-Andersson, Reneé, additional, Nyandoto, Paul, additional, Kononen, Juha, additional, Lepistö, Anna, additional, Poussa, Tuija, additional, Muhonen, Timo, additional, Ålgars, Annika, additional, and Isoniemi, Helena, additional

Published
2021
Full Text
View/download PDF

33. An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer

Author

Heervä, Eetu, primary, Väliaho, Vesa, additional, Salminen, Tapio, additional, Nieminen, Lasse, additional, Carpelan, Anu, additional, Kurki, Samu, additional, Sundström, Jari, additional, Huhtinen, Heikki, additional, Rantala, Arto, additional, Carpén, Olli, additional, Minn, Heikki, additional, Österlund, Pia, additional, Ålgars, Annika, additional, and Ristamäki, Raija, additional

Published
2020
Full Text
View/download PDF

37. Haiman edenneen neuroendokriinisen kasvaimen lääkehoito

Author

Ristamäki, Raija, Tarkkanen, Maija, Clinicum, and Syöpätautien osasto

Subjects
+drug therapy, Pancreatic Neoplasms, 3122 Syöpätaudit, Antineoplastic Agents, Everolimus, Neoplasm Metastasis, +therapeutic use, Somatostatin, Carcinoma, Neuroendocrine, +analogs & derivatives
Abstract

English summary

Published
2016

39. A nationwide study on parathyroid carcinoma

Author

Ryhänen, Eeva M., primary, Leijon, Helena, additional, Metso, Saara, additional, Eloranta, Eija, additional, Korsoff, Pirkko, additional, Ahtiainen, Petteri, additional, Kekäläinen, Päivi, additional, Tamminen, Marjo, additional, Ristamäki, Raija, additional, Knutar, Otto, additional, Löyttyniemi, Eliisa, additional, Niskanen, Leo, additional, Väisänen, Mika, additional, Heiskanen, Ilkka, additional, Välimäki, Matti J., additional, Laakso, Markku, additional, Haglund, Caj, additional, Arola, Johanna, additional, and Schalin-Jäntti, Camilla, additional

Published
2017
Full Text
View/download PDF

41. EGFRgene copy number predicts response to anti-EGFR treatment inRASwild type andRAS/BRAF/PIK3CAwild type metastatic colorectal cancer

Author

Ålgars, Annika, primary, Sundström, Jari, additional, Lintunen, Minnamaija, additional, Jokilehto, Terhi, additional, Kytölä, Soili, additional, Kaare, Milja, additional, Vainionpää, Reetta, additional, Orpana, Arto, additional, Österlund, Pia, additional, Ristimäki, Ari, additional, Carpen, Olli, additional, and Ristamäki, Raija, additional

Published
2016
Full Text
View/download PDF

43. EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Author

Carpen, Olli, primary, Ålgars, Annika, additional, Sundström, Jari, additional, Kytölä, Soili, additional, Österlund, Pia, additional, Lintunen, Minnamaija, additional, Jokilehto, Terhi, additional, Kaare, Milja, additional, Orpana, Arto, additional, Vainionpää, Reetta, additional, Ristimäki, Ari, additional, and Ristamäki, Raija, additional

Published
2016
Full Text
View/download PDF

44. Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study.

Author

Heervä, Eetu, Carpelan, Anu, Kurki, Samu, Sundström, Jari, Huhtinen, Heikki, Rantala, Arto, Ålgars, Annika, Ristamäki, Raija, Carpén, Olli, and Minn, Heikki

Subjects
ACADEMIC medical centers, AGE distribution, CANCER patients, CLINICAL medicine, COMBINED modality therapy, DECENTRALIZATION in management, MEDICAL databases, INFORMATION storage & retrieval systems, COLON tumors, LYMPH nodes, MULTIVARIATE analysis, ORGANIZATIONAL change, SEX distribution, SURVIVAL, RECTUM tumors, TUMOR classification, COMORBIDITY, TREATMENT effectiveness, PROPORTIONAL hazards models, PREOPERATIVE period, TUMOR grading, DIAGNOSIS, PROGNOSIS, TUMOR treatment
Abstract

Background: Most survival data in colorectal cancer (CRC) is derived from clinical trials or register-based studies. Hospital Biobanks, linked with hospital electronic records, could serve as a data-gathering method based on consecutively collected tumor samples. The aim of this Biobank study was to analyze survival of colorectal patients diagnosed and treated in a single-center university hospital over a period of 12 years, and to evaluate factors contributing to outcome. Material and methods: A total of 1777 patients with CRC treated during 2001-2012 were identified from the Auria Biobank, Turku, Finland. Longitudinal clinical information was collected from various hospital electronic records and date and cause of death obtained from Statistics Finland. Results: Cancer-specific, overall and disease-free survival was higher in patients diagnosed during 2004-2008 as compared with patients diagnosed in 2001-2003. Further improvement was not seen during years 2009-2012. Potential factors contributing to the improvement were introduction of multidisciplinary meetings, centralization of rectal cancer surgery, use of adjuvant chemotherapy and systematic preoperative radiotherapy of rectal cancer. The proportion of patients with stage I-IV CRC remained similar over the study period, but a marked decrease in non-metastatic rectal cancer with biopsy only (locally advanced disease) was observed. In stage I-III rectal cancer, Cox multivariate analysis suggested age, comorbidity, R1 resection, T staging and tumor grade as prognostic factors. In colon cancer, prognostic factors were age, comorbidity, gender and presence of lymph node metastases. Conclusions: Organizational changes in the treatment of CRC patients made since 2004 coincide with improved survival in CRC and a marked reduction in locally advanced rectal cancers. The clinical presentation of CRC has remained similar between 2001 and 2012. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

45. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Author

Manceau, Gilles, Imbeaud, Sandrine, Thiébaut, Raphaële, Liébaert, François, Fontaine, Karine, Rousseau, Francis, Génin, Bérengère, Le Corre, Delphine, Didelot, Audrey, Vincent, Marc, Bachet, Jean-Baptiste, Chibaudel, Benoist, Bouché, Olivier, Landi, Bruno, Bibeau, Frédéric, Leroy, Karen, Pénault-Llorca, Frederique, Van Laethem, Jean-Luc, Demetter, Pieter, Tejpar, Sabine, Rossi, Simona, Mosakhani, Neda, Osterlund, Pia, Ristamäki, Raija, Sarhadi, Virinder, Knuutila, Sakari, Boige, Valérie, André, Thierry, Laurent-Puig, Pierre, Manceau, Gilles, Imbeaud, Sandrine, Thiébaut, Raphaële, Liébaert, François, Fontaine, Karine, Rousseau, Francis, Génin, Bérengère, Le Corre, Delphine, Didelot, Audrey, Vincent, Marc, Bachet, Jean-Baptiste, Chibaudel, Benoist, Bouché, Olivier, Landi, Bruno, Bibeau, Frédéric, Leroy, Karen, Pénault-Llorca, Frederique, Van Laethem, Jean-Luc, Demetter, Pieter, Tejpar, Sabine, Rossi, Simona, Mosakhani, Neda, Osterlund, Pia, Ristamäki, Raija, Sarhadi, Virinder, Knuutila, Sakari, Boige, Valérie, André, Thierry, and Laurent-Puig, Pierre

Abstract

To identify microRNAs (miRNA) that predict response to anti-EGFR antibodies in patients with wild-type KRAS metastatic colorectal cancer (mCRC)., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2014

46. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/ BRAF/ PIK3CA wild type metastatic colorectal cancer.

Author

Ålgars, Annika, Sundström, Jari, Lintunen, Minnamaija, Jokilehto, Terhi, Kytölä, Soili, Kaare, Milja, Vainionpää, Reetta, Orpana, Arto, Österlund, Pia, Ristimäki, Ari, Carpen, Olli, and Ristamäki, Raija

Abstract

Anti-EGFR antibodies are used for the treatment of RAS wild type metastatic colorectal cancer. We previously showed that EGFR gene copy number (GCN) predicts response to anti-EGFR therapy in KRAS exon 2 wild type metastatic colorectal cancer. The aim of our study was to analyse the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. The material included 102 patients with KRAS exon 2 wild type metastatic colorectal cancer treated with anti-EGFR ± cytotoxic therapy. Next generation sequencing was used for KRAS, NRAS, BRAF and PIK3CA gene mutation analyses. EGFR GCN was analysed by EGFR immunohistochemistry guided automated silver in situ hybridisation. Increased EGFR GCN (≥4.0) predicted a better response and prolonged progression free survival in anti-EGFR treated RAS/BRAF/PIK3CA wild type patients (Log-rank test, p = 0.0004). In contrast, survival of RAS/BRAF/PIK3CA wild type, EGFR GCN below 4.0 patients did not differ from patients with mutant RAS, BRAF or PIK3CA. Our study indicates that EGFR GCN predicts anti-EGFR treatment efficacy in patients with RAS/BRAF/PIK3CA wt metastatic CRC. Tumours with EGFR GCN below 4.0 appear to be as refractory to anti-EGFR treatment as tumours with mutation in any of the RAS/RAF/PIK3CA pathway genes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Author

Manceau, Gilles, primary, Imbeaud, Sandrine, additional, Thiébaut, Raphaële, additional, Liébaert, François, additional, Fontaine, Karine, additional, Rousseau, Francis, additional, Génin, Bérengère, additional, Corre, Delphine Le, additional, Didelot, Audrey, additional, Vincent, Marc, additional, Bachet, Jean-Baptiste, additional, Chibaudel, Benoist, additional, Bouché, Olivier, additional, Landi, Bruno, additional, Bibeau, Frédéric, additional, Leroy, Karen, additional, Penault-Llorca, Frédérique, additional, Van Laethem, Jean-Luc, additional, Demetter, Pieter, additional, Tejpar, Sabine, additional, Rossi, Simona, additional, Mosakhani, Neda, additional, Österlund, Pia, additional, Ristamäki, Raija, additional, Sarhadi, Virinder, additional, Knuutila, Sakari, additional, Boige, Valérie, additional, André, Thierry, additional, and Laurent-Puig, Pierre, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results